Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arrowhead Pharmaceuticals (ARWR) Return on Assets (2016 - 2025)

Arrowhead Pharmaceuticals' Return on Assets history spans 15 years, with the latest figure at 0.16% for Q4 2025.

  • For Q4 2025, Return on Assets rose 76.0% year-over-year to 0.16%; the TTM value through Dec 2025 reached 0.16%, up 76.0%, while the annual FY2025 figure was 0.02%, 66.0% up from the prior year.
  • Return on Assets reached 0.16% in Q4 2025 per ARWR's latest filing, up from 0.02% in the prior quarter.
  • In the past five years, Return on Assets ranged from a high of 0.16% in Q4 2025 to a low of 0.6% in Q1 2024.
  • Average Return on Assets over 5 years is 0.26%, with a median of 0.2% recorded in 2022.
  • Peak YoY movement for Return on Assets: crashed -43bps in 2024, then skyrocketed 76bps in 2025.
  • A 5-year view of Return on Assets shows it stood at 0.27% in 2021, then grew by 28bps to 0.2% in 2022, then crashed by -122bps to 0.44% in 2023, then crashed by -39bps to 0.6% in 2024, then surged by 126bps to 0.16% in 2025.
  • Per Business Quant, the three most recent readings for ARWR's Return on Assets are 0.16% (Q4 2025), 0.02% (Q3 2025), and 0.11% (Q2 2025).